1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This Funding Opportunity Announcement (FOA) solicits Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) to develop medium- to high-throughput assays to evaluate the effects of toxicants on pluripotent or induced pluripotent cells with respect to cell differentiation and the resulting differentiated cell populations. The ability to incorporate genetic diversity in these assays would be useful.These assays will provide information on mechanisms of chemically-induced biological activity, help to prioritize chemicals for more extensive toxicological evaluation, support more predictive models of in vivo biological response, and potentially inform on the role of genetic diversity in toxicological effects.
Funding Opportunity Number: RFA-ES-15-005. Assistance Listing: 93.113. Funding Instrument: G. Category: ENV,HL. Award Amount: Up to $225K per award.
Get alerted about grants like this
Save a search for “National Institutes of Health” or related topics and get emailed when new opportunities appear.
Search similar grants →Based on current listing details, eligibility includes: Eligible applicants: Small businesses. Other Eligible Applicants include the following: Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria: 1. Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; 2. Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; 3. i. SBIR and STTR. Be a concern which is more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR ii. SBIR-only. Be a concern which is more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; OR iii. SBIR and STTR. Be a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with § 121.705(b) concerning registration and proposal requirements. 4. Has, including its affiliates, not more than 500 employees. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Up to $225K per award Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is February 19, 2015. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
Purpose. This FOA issued by the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Neurological Disorders and Stroke (NINDS) solicits Research Project Grant (R01) applications from institutions/organizations that propose to conduct basic and translational research into the neurobiology of pain in sickle cell disease. Applications that promote multidisciplinary collaboration are strongly encouraged. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) grant mechanism. Funds Available and Anticipated Number of Awards. NHLBI intends to commit up to $6.0 million (total costs) over four years and NINDS intends to commit up to $1.4 million (total costs) over four years.The NHLBI and NINDS anticipate that they will award up to $1.85 million in FY 2009 to fund four applications in response to this FOA.Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Funding Opportunity Number: RFA-HL-09-008. Assistance Listing: 93.839,93.853. Funding Instrument: G. Category: HL. Award Amount: Up to $300K per award.
Purpose.This Funding Opportunity Announcement (FOA), issued by the National Institute of Mental Health (NIMH), solicits Exploratory/Developmental Phased Innovation (R21/R33) grant applications from institutions or organizations that propose to generate and characterize induced pluripotent stem (iPS) cells from human control and/or patient populations with cognitive, affective, social, sleep and developmental brain disorders. This can, but does not need to, include disorders in which a genetic linkage has already been inferred. Applications that combine expertise in stem cell biology, cortical development and the clinical study or treatment of mental disorders are strongly encouraged. Responsive applications will place an emphasis on appropriate validation of iPS cells and their derivatives, evaluating the hetero/homogeneity of any cell populations to be screened and use of cellular assays relevant to brain function and mental disorders. Studies involving the acquisition of tissue from new subjects should include provisions to archive and distribute non-induced (e.g., primary) cells. Since studies likely require several areas of expertise, applicants are encouraged to include multiple PIs on the application. Funding Opportunity Number: RFA-MH-09-130. Assistance Listing: 93.242. Funding Instrument: G. Category: HL. Award Amount: Up to $200K per award.
Purpose. Under this Funding Opportunity Announcement (FOA), the National Institute on Alcohol Abuse and Alcoholism requests Research Project Grant (R01) applications: 1) to test innovative single and combined pharmacologic therapies for alcohol use disorders in HIV+ populations for the purpose of improving adherence to antiretroviral medications, reducing the rate of viral mutation and toxicity related to alcohol-ARV interactions, and reducing sexual risk-taking; and 2) to assess the potential usefulness of medications for alcohol use disorders in preventing secondary HIV infections in targeted high risk populations of gay men and minority women. Mechanism of Support. This FOA will utilize the R01 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-AA-09-008, that solicits applications under the expanded R03 grant mechanism to do initial studies of the safety and feasibility of pharmacotherapies for alcohol use disorders in HIV-infected populations. Funds Available and Anticipated Number of Awards. A total of $3.0 M will be awarded and 4-6 awards are anticipated. Funding Opportunity Number: RFA-AA-09-007. Assistance Listing: 93.273. Funding Instrument: G. Category: HL. Award Amount: $3M total program funding.